EA020792B1 - Пептиды трав для вакцины - Google Patents
Пептиды трав для вакцины Download PDFInfo
- Publication number
- EA020792B1 EA020792B1 EA201171001A EA201171001A EA020792B1 EA 020792 B1 EA020792 B1 EA 020792B1 EA 201171001 A EA201171001 A EA 201171001A EA 201171001 A EA201171001 A EA 201171001A EA 020792 B1 EA020792 B1 EA 020792B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- sequence
- polypeptide
- peptides
- peptide
- amino acids
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 601
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 442
- 244000025254 Cannabis sativa Species 0.000 title description 38
- 101100449439 Drosophila melanogaster grass gene Proteins 0.000 title description 37
- 229960005486 vaccine Drugs 0.000 title description 14
- 239000000203 mixture Substances 0.000 claims abstract description 176
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 34
- 230000007815 allergy Effects 0.000 claims abstract description 30
- 208000026935 allergic disease Diseases 0.000 claims abstract description 22
- 229920001184 polypeptide Polymers 0.000 claims description 223
- 150000001413 amino acids Chemical class 0.000 claims description 102
- 238000000034 method Methods 0.000 claims description 42
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 41
- 206010048908 Seasonal allergy Diseases 0.000 claims description 35
- 238000011282 treatment Methods 0.000 claims description 34
- 208000010668 atopic eczema Diseases 0.000 claims description 30
- 230000000172 allergic effect Effects 0.000 claims description 29
- 229940046528 grass pollen Drugs 0.000 claims description 24
- 238000011321 prophylaxis Methods 0.000 claims description 16
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims description 8
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 230000004048 modification Effects 0.000 claims description 7
- 238000012986 modification Methods 0.000 claims description 7
- 210000004899 c-terminal region Anatomy 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 201000004338 pollen allergy Diseases 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 230000013595 glycosylation Effects 0.000 claims description 3
- 238000006206 glycosylation reaction Methods 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 2
- 230000026731 phosphorylation Effects 0.000 claims description 2
- 238000006366 phosphorylation reaction Methods 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 241001488747 Elusa Species 0.000 claims 1
- 230000021736 acetylation Effects 0.000 claims 1
- 238000006640 acetylation reaction Methods 0.000 claims 1
- 230000009435 amidation Effects 0.000 claims 1
- 238000007112 amidation reaction Methods 0.000 claims 1
- 241000238711 Pyroglyphidae Species 0.000 abstract description 3
- 229940046533 house dust mites Drugs 0.000 abstract description 3
- 239000013566 allergen Substances 0.000 description 119
- 235000001014 amino acid Nutrition 0.000 description 92
- 229940024606 amino acid Drugs 0.000 description 92
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 79
- 229960004784 allergens Drugs 0.000 description 70
- 239000002157 polynucleotide Substances 0.000 description 52
- 108091033319 polynucleotide Proteins 0.000 description 52
- 102000040430 polynucleotide Human genes 0.000 description 52
- 210000004027 cell Anatomy 0.000 description 51
- 108090000623 proteins and genes Proteins 0.000 description 50
- 235000008216 herbs Nutrition 0.000 description 43
- 235000018102 proteins Nutrition 0.000 description 41
- 102000004169 proteins and genes Human genes 0.000 description 41
- 229960001340 histamine Drugs 0.000 description 40
- 239000013598 vector Substances 0.000 description 37
- 238000004458 analytical method Methods 0.000 description 30
- 235000014347 soups Nutrition 0.000 description 30
- 102000004127 Cytokines Human genes 0.000 description 29
- 108090000695 Cytokines Proteins 0.000 description 29
- 239000000427 antigen Substances 0.000 description 28
- 108091007433 antigens Proteins 0.000 description 28
- 102000036639 antigens Human genes 0.000 description 28
- 244000052363 Cynodon dactylon Species 0.000 description 26
- 241000746983 Phleum pratense Species 0.000 description 24
- 102000043131 MHC class II family Human genes 0.000 description 23
- 108091054438 MHC class II family Proteins 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 23
- 240000004296 Lolium perenne Species 0.000 description 22
- 239000012634 fragment Substances 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 230000002209 hydrophobic effect Effects 0.000 description 17
- 230000004044 response Effects 0.000 description 17
- 230000007935 neutral effect Effects 0.000 description 15
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 15
- 230000001939 inductive effect Effects 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 238000012217 deletion Methods 0.000 description 13
- 230000037430 deletion Effects 0.000 description 13
- 150000007523 nucleic acids Chemical class 0.000 description 13
- 108700028369 Alleles Proteins 0.000 description 11
- 241000416915 Roa Species 0.000 description 11
- 210000000612 antigen-presenting cell Anatomy 0.000 description 11
- 238000000586 desensitisation Methods 0.000 description 11
- 239000013641 positive control Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 125000003275 alpha amino acid group Chemical group 0.000 description 10
- 210000003651 basophil Anatomy 0.000 description 10
- 239000002689 soil Substances 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 8
- 230000006052 T cell proliferation Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000013574 grass pollen allergen Substances 0.000 description 8
- 230000028993 immune response Effects 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 238000012384 transportation and delivery Methods 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 241000209504 Poaceae Species 0.000 description 6
- -1 aromatic amino acid Chemical class 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 210000003630 histaminocyte Anatomy 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 241000209049 Poa pratensis Species 0.000 description 5
- 206010070834 Sensitisation Diseases 0.000 description 5
- 108091008874 T cell receptors Proteins 0.000 description 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 5
- 244000152045 Themeda triandra Species 0.000 description 5
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 5
- 125000001931 aliphatic group Chemical group 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 4
- 208000001840 Dandruff Diseases 0.000 description 4
- 241000209082 Lolium Species 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000002716 delivery method Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- 206010039085 Rhinitis allergic Diseases 0.000 description 3
- 206010039101 Rhinorrhoea Diseases 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 208000030961 allergic reaction Diseases 0.000 description 3
- 201000010105 allergic rhinitis Diseases 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000004459 forage Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 235000009973 maize Nutrition 0.000 description 3
- 229940023041 peptide vaccine Drugs 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 2
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- 235000003097 Artemisia absinthium Nutrition 0.000 description 2
- 240000001851 Artemisia dracunculus Species 0.000 description 2
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 235000018185 Betula X alpestris Nutrition 0.000 description 2
- 235000018212 Betula X uliginosa Nutrition 0.000 description 2
- 244000281762 Chenopodium ambrosioides Species 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 241000380130 Ehrharta erecta Species 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 206010052140 Eye pruritus Diseases 0.000 description 2
- 241000234642 Festuca Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 244000060234 Gmelina philippensis Species 0.000 description 2
- 241000257303 Hymenoptera Species 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102000003816 Interleukin-13 Human genes 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 102000006386 Myelin Proteins Human genes 0.000 description 2
- 108010083674 Myelin Proteins Proteins 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 208000036071 Rhinorrhea Diseases 0.000 description 2
- 240000003152 Rhus chinensis Species 0.000 description 2
- 235000014220 Rhus chinensis Nutrition 0.000 description 2
- 241000555745 Sciuridae Species 0.000 description 2
- 241000287219 Serinus canaria Species 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 241001520823 Zoysia Species 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 229940074608 allergen extract Drugs 0.000 description 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical group CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 235000003484 annual ragweed Nutrition 0.000 description 2
- 239000001138 artemisia absinthium Substances 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000006263 bur ragweed Nutrition 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 235000003488 common ragweed Nutrition 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 230000001712 encephalitogenic effect Effects 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000013568 food allergen Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 229940076144 interleukin-10 Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical group OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 235000020232 peanut Nutrition 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 238000011170 pharmaceutical development Methods 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000013573 pollen allergen Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000021251 pulses Nutrition 0.000 description 2
- 235000009736 ragweed Nutrition 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940035024 thioglycerol Drugs 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- LZOIGVDSAMDBIO-LXWJMTKESA-N (2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](N)CCSC)C1=CC=CC=C1 LZOIGVDSAMDBIO-LXWJMTKESA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- IXHBSOXJLNEOPY-UHFFFAOYSA-N 2'-anilino-6'-(n-ethyl-4-methylanilino)-3'-methylspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound C=1C=C(C2(C3=CC=CC=C3C(=O)O2)C2=CC(NC=3C=CC=CC=3)=C(C)C=C2O2)C2=CC=1N(CC)C1=CC=C(C)C=C1 IXHBSOXJLNEOPY-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- 241000759901 Adenanthos sericeus Species 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 229940122450 Altered peptide ligand Drugs 0.000 description 1
- 240000002470 Amphicarpaea bracteata Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 101100077952 Arabidopsis thaliana MRL7 gene Proteins 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 241001674044 Blattodea Species 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000723418 Carya Species 0.000 description 1
- 244000068645 Carya illinoensis Species 0.000 description 1
- 235000009025 Carya illinoensis Nutrition 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 244000103926 Chamaenerion angustifolium Species 0.000 description 1
- 235000006890 Chamerion angustifolium subsp angustifolium Nutrition 0.000 description 1
- 235000002278 Chamerion angustifolium subsp circumvagum Nutrition 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000289659 Erinaceidae Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000234645 Festuca pratensis Species 0.000 description 1
- 241000508723 Festuca rubra Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 240000004153 Hibiscus sabdariffa Species 0.000 description 1
- 235000001018 Hibiscus sabdariffa Nutrition 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 241001098499 Lanceolata Species 0.000 description 1
- 241001661426 Litus Species 0.000 description 1
- 108010066345 MHC binding peptide Proteins 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 101100109406 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) aga-1 gene Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 101800004192 Peptide P1 Proteins 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 102100026918 Phospholipase A2 Human genes 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 244000305267 Quercus macrolepis Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 235000005291 Rumex acetosa Nutrition 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 240000002439 Sorghum halepense Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000779819 Syncarpia glomulifera Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
- 241001106462 Ulmus Species 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 239000003659 bee venom Substances 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000013575 birch pollen allergen Substances 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000024346 drought recovery Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000004174 erythrosine Substances 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N ethyl acetate Substances CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000000367 exoproteolytic effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000054999 human core Human genes 0.000 description 1
- 108700026469 human core Proteins 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 201000002266 mite infestation Diseases 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 229940023146 nucleic acid vaccine Drugs 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000001739 pinus spp. Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 108010005636 polypeptide C Proteins 0.000 description 1
- 230000012354 positive regulation of binding Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 235000003513 sheep sorrel Nutrition 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229950002929 trinitrophenol Drugs 0.000 description 1
- 229940036248 turpentine Drugs 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A61K39/36—Allergens from pollen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0901927.4A GB0901927D0 (en) | 2009-02-05 | 2009-02-05 | Peptide for IL10 production |
| GB0901928A GB0901928D0 (en) | 2009-02-05 | 2009-02-05 | Peptides for vaccine |
| GB0912578A GB0912578D0 (en) | 2009-07-20 | 2009-07-20 | Peptide for IL-10 production |
| PCT/GB2009/001995 WO2010018384A1 (en) | 2008-08-15 | 2009-08-14 | T-cell antigen peptide from allergen for stimulation of il-10 production |
| GB0917871A GB0917871D0 (en) | 2009-10-12 | 2009-10-12 | Peptides for vaccine |
| PCT/GB2010/000198 WO2010089554A1 (en) | 2009-02-05 | 2010-02-05 | Peptides for vaccine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201171001A1 EA201171001A1 (ru) | 2012-02-28 |
| EA020792B1 true EA020792B1 (ru) | 2015-01-30 |
Family
ID=42082585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201171001A EA020792B1 (ru) | 2009-02-05 | 2010-02-05 | Пептиды трав для вакцины |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8753644B2 (enExample) |
| EP (2) | EP2393830B8 (enExample) |
| JP (2) | JP5746053B2 (enExample) |
| KR (1) | KR20110111307A (enExample) |
| CN (2) | CN102307893B (enExample) |
| AU (1) | AU2010212193B2 (enExample) |
| BR (1) | BRPI1008802A2 (enExample) |
| CA (1) | CA2751500A1 (enExample) |
| DK (1) | DK2393830T3 (enExample) |
| EA (1) | EA020792B1 (enExample) |
| ES (1) | ES2532759T3 (enExample) |
| GB (1) | GB2469894B (enExample) |
| HK (1) | HK1212358A1 (enExample) |
| HR (1) | HRP20150317T1 (enExample) |
| IL (1) | IL214257A (enExample) |
| MX (1) | MX2011008179A (enExample) |
| NZ (1) | NZ594268A (enExample) |
| PL (1) | PL2393830T3 (enExample) |
| PT (1) | PT2393830E (enExample) |
| SG (1) | SG173523A1 (enExample) |
| SI (1) | SI2393830T1 (enExample) |
| WO (1) | WO2010089554A1 (enExample) |
| ZA (1) | ZA201105436B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2393830T1 (sl) * | 2009-02-05 | 2015-04-30 | Circassia Limited | Travni peptidi za cepivo |
| CN107320734A (zh) * | 2011-04-29 | 2017-11-07 | 西莱克塔生物科技公司 | 从合成纳米载体中控制释放免疫抑制剂 |
| CN105307641A (zh) | 2013-05-03 | 2016-02-03 | 西莱克塔生物科技公司 | 用于降低不期望体液免疫应答的给药组合 |
| EA201790551A1 (ru) | 2014-09-07 | 2017-07-31 | Селекта Байосайенсиз, Инк. | Способы и композиции для ослабления иммунных ответов к пропускающему экзон вирусному трансферному вектору |
| WO2017004561A1 (en) | 2015-07-01 | 2017-01-05 | Alk-Abelló A/S | Peptide combinations and uses thereof for treating grass allergy |
| EP4599848A3 (en) | 2017-03-11 | 2025-12-03 | Cartesian Therapeutics, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| EP3672600A4 (en) | 2017-08-21 | 2021-05-19 | Glycom A/S | SYNTHETIC COMPOSITION TO REDUCE ALLERGY SYMPTOMS |
| CN108802216B (zh) * | 2018-05-23 | 2021-04-16 | 山东出入境检验检疫局检验检疫技术中心 | 一种使用区域敏感性蛋白组和/或多肽组鉴别刺参产地的方法 |
| US12553041B2 (en) | 2019-06-04 | 2026-02-17 | Cartesian Therapeutics Inc. | Formulations and doses of pegylated uricase |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996003106A2 (en) * | 1994-07-26 | 1996-02-08 | University Of Manitoba | Allergenic peptides derived from poa pratensis |
| WO2003024998A1 (en) * | 2001-09-18 | 2003-03-27 | Monash University | T cell epitopes of the cyn d 1 allergen from bermuda grass pollen |
| WO2006008018A1 (de) * | 2004-07-21 | 2006-01-26 | Merck Patent Gmbh | Varianten der gruppe 1-allergene aus poaceae mit reduzierter allergenität und erhaltener t-zellreaktivität |
| WO2007140505A2 (en) * | 2006-06-09 | 2007-12-13 | Biomay Ag | Vaccine carrier |
| WO2009022157A2 (en) * | 2007-08-15 | 2009-02-19 | Circassia Limited | Peptide with improved solubility |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1340729C (en) | 1988-03-23 | 1999-09-07 | Mohan Bir Singh | Ryegrass pollen allergen |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| CA2089735C (en) | 1990-08-17 | 2008-03-18 | Mohan Bir Singh | Ryegrass pollen allergen |
| WO1992016554A1 (en) | 1991-03-14 | 1992-10-01 | The University Of Melbourne | Protein allergens of the species cynodon dactylon |
| WO1994001560A1 (en) | 1991-07-12 | 1994-01-20 | Immulogic Pharmaceutical Corporation | Allergenic proteins and peptides from japanese cedar pollen |
| EP0665888B2 (en) | 1991-08-16 | 2007-07-25 | The University Of Melbourne | Ryegrass pollen allergen |
| EP0668915A1 (en) | 1991-11-15 | 1995-08-30 | The University Of Melbourne | Protein allergens of the species cynodon dactylon |
| US6441157B1 (en) | 1991-11-15 | 2002-08-27 | University Of Melbourne | Nucleic acid sequences encoding protein allergens of the species Cynodon dactylon |
| ATE283281T1 (de) | 1992-08-14 | 2004-12-15 | Univ Melbourne | T-zell epitope des raygraspollen-allergens |
| US5480972A (en) | 1992-10-30 | 1996-01-02 | The University Of Melbourne | Allergenic proteins from Johnson grass pollen |
| US6214358B1 (en) | 1992-10-30 | 2001-04-10 | Immulogic Pharamaceutical Corp. | Protein allergens of the species Cynodon dactylon |
| NZ263913A (en) * | 1993-03-12 | 1997-10-24 | Immulogic Pharma Corp | Lol pi protein allergen from ryegrass and related peptides coding sequences, vectors, protein production and use |
| FI960629L (fi) * | 1993-08-13 | 1996-04-12 | Immulogic Pharma Corp | Raiheinäsiitepöly allergeenin T-soluepitoopit |
| US5968526A (en) | 1994-04-14 | 1999-10-19 | Immulogic Pharamaceutical Corporation | T cell epitopes of the major allergens from Dermatophagoides (house dust mite) |
| GB9412714D0 (en) | 1994-06-24 | 1994-08-17 | Lewin Ian V | T cill epitopes |
| US7112333B1 (en) | 1994-08-05 | 2006-09-26 | Heska Corporation | T cell epitopes of ryegrass pollen allergen |
| IL115744A (en) | 1994-10-27 | 2000-07-16 | Akzo Nobel Nv | Peptides comprising a subsequence of human cartilage glycoprotein - 39 |
| AT402505B (de) | 1995-08-02 | 1997-06-25 | Biomay Prod & Handel | Rekombinantes 60 kda pflanzliches panallergen (kofaktor-unabhängige phosphoglyceratmutase; e.c. 5.4.2.1.) |
| JP2002500198A (ja) | 1998-01-09 | 2002-01-08 | サーカシア リミテッド | 脱感作のための方法及び組成物 |
| DE19823097A1 (de) * | 1998-05-22 | 1999-11-25 | Max Planck Gesellschaft | Mittel gegen saisonale Typ-I-Allergien und bakterielle Infektionen |
| US6989146B2 (en) | 2000-08-09 | 2006-01-24 | The Regents Of The University Of California | Stress proteins and peptides and methods of use thereof |
| WO2003047618A2 (en) | 2001-12-05 | 2003-06-12 | Circassia Limited | Immunotherapeutic methods and systems |
| AUPS148202A0 (en) | 2002-04-02 | 2002-05-09 | Monash University | Immunotherapeutic and immunoprophylactic reagents |
| AU2003228133A1 (en) | 2002-04-22 | 2003-11-03 | Umc Utrecht Holding B.V. | Reduction of unwanted immune reactions |
| GB0210741D0 (en) | 2002-05-10 | 2002-06-19 | Medical Res Council | Methods of therapy |
| GB0308988D0 (en) | 2003-04-17 | 2003-05-28 | Univ Singapore | Molecule |
| WO2006075253A2 (en) | 2005-01-11 | 2006-07-20 | Commissariat A L'energie Atomique | Peptides for desensitizing subjects allergic to dog hair and dander and compositions containing said peptides. |
| WO2006132607A1 (en) | 2005-06-10 | 2006-12-14 | National University Of Singapore | Mutant allergen(s) |
| DE202005009990U1 (de) * | 2005-06-25 | 2006-11-02 | Hengst Gmbh & Co.Kg | Vorrichtung zum Abscheiden von Ölteilchen aus dem Kurbelgehäuseentlüftungsgas einer Brennkraftmaschine |
| US20070092532A1 (en) | 2005-10-25 | 2007-04-26 | Board Of Trustees Operating Michigan State University | Arthritis vaccines and methods |
| DK2119450T3 (da) | 2005-11-29 | 2013-05-06 | Actogenix Nv | Induktion af mucosal tolerance over for pankreatisk ø-beta-celle-autoantigener |
| US20110038881A1 (en) | 2007-05-09 | 2011-02-17 | Circassia Limited | Prognostic assay for determining t cell response to hla antigens and use thereof in field of tissue transplantation |
| GB0710529D0 (en) | 2007-06-01 | 2007-07-11 | Circassia Ltd | Vaccine |
| EP2042193A1 (en) | 2007-09-28 | 2009-04-01 | Biomay AG | RNA Vaccines |
| US8821887B2 (en) | 2008-08-15 | 2014-09-02 | Circassia Limited | T-cell antigen peptide from allergen for stimulation of IL-10 production |
| SI2393830T1 (sl) * | 2009-02-05 | 2015-04-30 | Circassia Limited | Travni peptidi za cepivo |
-
2010
- 2010-02-05 SI SI201030898T patent/SI2393830T1/sl unknown
- 2010-02-05 SG SG2011055951A patent/SG173523A1/en unknown
- 2010-02-05 WO PCT/GB2010/000198 patent/WO2010089554A1/en not_active Ceased
- 2010-02-05 DK DK10704399T patent/DK2393830T3/en active
- 2010-02-05 AU AU2010212193A patent/AU2010212193B2/en not_active Ceased
- 2010-02-05 PT PT107043994T patent/PT2393830E/pt unknown
- 2010-02-05 GB GB1001954A patent/GB2469894B/en not_active Expired - Fee Related
- 2010-02-05 ES ES10704399.4T patent/ES2532759T3/es active Active
- 2010-02-05 CA CA2751500A patent/CA2751500A1/en not_active Abandoned
- 2010-02-05 MX MX2011008179A patent/MX2011008179A/es active IP Right Grant
- 2010-02-05 NZ NZ594268A patent/NZ594268A/xx not_active IP Right Cessation
- 2010-02-05 HR HRP20150317TT patent/HRP20150317T1/hr unknown
- 2010-02-05 PL PL10704399T patent/PL2393830T3/pl unknown
- 2010-02-05 EP EP10704399.4A patent/EP2393830B8/en not_active Not-in-force
- 2010-02-05 KR KR1020117019157A patent/KR20110111307A/ko not_active Ceased
- 2010-02-05 JP JP2011548765A patent/JP5746053B2/ja not_active Expired - Fee Related
- 2010-02-05 EA EA201171001A patent/EA020792B1/ru not_active IP Right Cessation
- 2010-02-05 EP EP15152164.8A patent/EP2891662A1/en not_active Withdrawn
- 2010-02-05 CN CN201080006665.3A patent/CN102307893B/zh not_active Expired - Fee Related
- 2010-02-05 CN CN201410056647.6A patent/CN103784952B/zh not_active Expired - Fee Related
- 2010-02-05 BR BRPI1008802A patent/BRPI1008802A2/pt not_active IP Right Cessation
- 2010-02-05 US US13/148,024 patent/US8753644B2/en not_active Expired - Fee Related
-
2011
- 2011-07-22 ZA ZA2011/05436A patent/ZA201105436B/en unknown
- 2011-07-24 IL IL214257A patent/IL214257A/en not_active IP Right Cessation
-
2012
- 2012-01-10 HK HK16100075.0A patent/HK1212358A1/en unknown
-
2014
- 2014-05-19 US US14/281,089 patent/US20140302071A1/en not_active Abandoned
-
2015
- 2015-05-07 JP JP2015094636A patent/JP6215252B2/ja not_active Expired - Fee Related
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996003106A2 (en) * | 1994-07-26 | 1996-02-08 | University Of Manitoba | Allergenic peptides derived from poa pratensis |
| WO2003024998A1 (en) * | 2001-09-18 | 2003-03-27 | Monash University | T cell epitopes of the cyn d 1 allergen from bermuda grass pollen |
| WO2006008018A1 (de) * | 2004-07-21 | 2006-01-26 | Merck Patent Gmbh | Varianten der gruppe 1-allergene aus poaceae mit reduzierter allergenität und erhaltener t-zellreaktivität |
| WO2007140505A2 (en) * | 2006-06-09 | 2007-12-13 | Biomay Ag | Vaccine carrier |
| WO2009022157A2 (en) * | 2007-08-15 | 2009-02-19 | Circassia Limited | Peptide with improved solubility |
| WO2009022154A2 (en) * | 2007-08-15 | 2009-02-19 | Circassia Limited | Peptide with multiple epitopes |
Non-Patent Citations (2)
| Title |
|---|
| JUTEL ET AL.: "Allergen-specific immunotherapy with recombinant grass pollen allergens". JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY, INC, US LNKD-DOI: 10.1016/J. JACI. 2005. 06. 004, vol. 116, no. 3, 1 September 2005 (2005-09-01), pages 608-613, XP005068191, ISSN: 0091-6749, abstract * |
| SWOBODA INES ET AL.: "Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE-binding capacity: candidates for grass pollen-specific immunotherapy". EUROPEAN JOURNAL OF IMMUNOLOGY JAN 2002 LNKD-PUBMED: 11782018, vol. 32, no. 1, January 2002 (2002-01), pages 270-280, XP002581444, ISSN: 0014-2980, abstract * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101699554B1 (ko) | 백신용 펩티드 | |
| DK2079481T4 (en) | Vaccine peptide combinations against cat allergy | |
| JP5788319B2 (ja) | ブタクサアレルギーの治療用のＡｍｂａ１ペプチド | |
| JP6215252B2 (ja) | ワクチン用ペプチド | |
| CN102762225B (zh) | 用于针对桦树过敏的疫苗的肽 | |
| CN105120894A (zh) | 新颖的免疫治疗分子和其用途 | |
| RU2689552C2 (ru) | Новая иммунотерапевтическая композиция и ее применения | |
| US20090098167A1 (en) | PHL P 1 Allergen Derivative | |
| CN116490207A (zh) | 基于桦树花粉变应原和苹果变应原的重组多肽 | |
| HK1197371A (en) | Grass peptides for vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |